The FDA concluded a general inspection of the Nitto Avecia Pharma Services laboratories from July 21 to July 25. 2025.

This routine audit, typically performed by the agency every two years, evaluated the firm’s quality systems, laboratory procedures, data integrity practices, and investigation handling.

Following the review, the facilities were determined to be fully compliant with industry and FDA standards, resulting in zero Form 483 observations.

This achievement further highlights Nitto Avecia Pharma Services’ unwavering commitment to quality and continuous improvement.